A Randomized, Double-Blind, Three-Arm Study Comparing Combination to Monthly Alternating Nucleoside Therapy for the Treatment of Advanced HIV Disease (CD4 <= 50/mm3) With a Prior History of Nucleoside Therapy

Inclusion Criteria

Inclusion Criteria

Concurrent Medication:

Required:

- PCP prophylaxis.

Allowed:

- Erythropoietin.

- Prophylaxis for MAI or fungal infections.

- Antibiotics.

- Over-the-counter, alternative, or regularly prescribed drugs.

- Steroids, if for < 21 days.

Concurrent Treatment:

Allowed:

- Radiation therapy for cutaneous Kaposi's sarcoma.

Patients must have:

- HIV infection.

- CD4 count <= 50 cells/mm3.

- Prior nucleoside monotherapy for at least 6 months.

- Life expectancy of at least 6 months.

Prior Medication: Required:

- Nucleoside monotherapy for at least 6 months. Active alcohol or drug abuse.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

- Severe peripheral neuropathy.

- Psychological or emotional problems sufficient to prevent study compliance.

Concurrent Medication:

Excluded:

- Systemic chemotherapy for malignancy.

- Acute or induction therapy for opportunistic infection.

Patients with the following prior conditions are excluded:

- History of acute or chronic pancreatitis.

- Grade 3 or greater toxicity to AZT, ddI, or ddC on two or more occasions.

Prior Medication:

Excluded:

- Non-study nucleosides or biologic response modifiers within 7 days prior to study
entry.

- Acute therapy for opportunistic process within 14 days prior to study entry.

- Acute systemic therapy for other medical conditions within 14 days prior to study
entry.